

6 October 2023

ValiRx PLC ("ValiRx" or the "Company")

Statement re Share Price Movement

London, UK - ValiRx Plc (AIM: VAL), a life science company focusing on early-stage cancer therapeutics and women's health, notes the recent increase in the Company's share price and confirms that it is not in possession of unpublished price sensitive information.

The Company notes the announcement published by EUDA Health Holdings Limited in relation to its proposed merger with TheoremRx Inc. The announcement can be viewed in full at the link below:

<https://www.globenewswire.com/news-release/2023/10/05/2755433/0/en/EUDA-Health-Holdings-Limited-Enters-into-Letter-of-Intent-for-Proposed-Merger-with-TheoremRx-Inc.html>

As initially announced on 2 November 2021, VAL201, the Company's clinical asset for prostate cancer, remains subject to the Letter of Intent with TheoremRx Inc.

The Directors of the Company take responsibility for this announcement.

*** ENDS ***

For more information, please contact:

ValiRx plc Dr Suzanne Dilly, CEO	Tel: +44 (0) 2476 796496 www.valirx.com Suzanne.Dilly@valirx.com
V Formation (Public Relations) Lucy Wharton - Senior PR Executive Sue Carr - Director	+44 (0) 115 787 0206 www.vformation.biz lucy@vformation.biz sue@vformation.biz
Cairn Financial Advisers LLP (Nominated Adviser) Liam Murray/ Ludovico Lazzaretti	Tel: +44 (0) 20 7213 0880
Cavendish Securities plc (Joint Broker) Dale Bellis/Michael Johnson (Sales) Callum Davidson/Giles Balleny (Corporate Finance)	Tel: +44 (0) 20 7397 8900
Turner Pope Investments (Joint Broker) James Pope / Andy Thacker	Tel: +44 (0) 20 3657 0050

Notes for Editors

About ValiRx

ValiRx is a life science company focused on early-stage cancer therapeutics and women's health, accelerating the translation of innovative science into impactful medicines to improve patient lives.

ValiRx provides the scientific, financial, and commercial framework for enabling rapid translation of innovative science into clinical development.

Using its extensive and proven experience in research and drug development, the team at ValiRx selects and incubates promising novel drug candidates and guides them through an optimised process of development, from pre-clinical studies to clinic and investor-ready assets.

ValiRx connects diverse disciplines across scientific, technical, and commercial domains, with the aim of achieving a more streamlined, less costly, drug development process. The team works closely with carefully selected collaborators and leverages the combined expertise required for science to advance.

Lead candidates from ValiRx's portfolio are outlicensed or partnered with investors through ValiRx subsidiary companies for further clinical development and commercialisation.

ValiRx listed on the AIM Market of the London Stock Exchange in October 2006 and trades under the ticker symbol: VAL.

For further information, visit: www.valirx.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@seg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

SPMFSESUMEDSELS